Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BG9588 in Proliferative Lupus Glomerulonephritis
NCT00001789Phase 2Completed
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- Start
- Jun 1999
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ruplizumab in lupus nephritis (LN), sponsored by National Institute of Arthritis and Musculoskeletal and Skin Diseases. Started Jun 1999; status: completed.
02
Drugs
ruplizumab
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on NCT00001789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001789.